Regulatory and Development Update
Filed with ASX · · 2 pages · English
02 January 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to provide an update on the regulatory and clinical development status of its investigational new treatment for Amyotrophic Lateral Sclerosis (AL
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- New Funding Secured for HEALEY ALS Platform Trial
- Equity Raising Presentation
- Trading Halt
- FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
- Neurizon Completes GMP Tablet Registration Batches
Later from Neurizon Therapeutics
- Global Trademark Protection Secured Across Key Markets
- Neurizon Completes Entitlement Offer
- Neurizon secures $6million R&D Tax Incentive Rebate
- Appendix 4C & Quarterly Update
- Appendix 4D - Half-year Financial Report - 31 December 2025
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics